B7-H3 is overexpressed in most human cancers, and clinical trials of anti-B7-H3 antibodies against melanoma 67, head and neck squamous cell carcinoma 1, and non-small cell lung cancer are ongoing 43, but the underlying mechanisms of B7-H3 expression remains unclear. Here, CD276 is linked to non-small cell lung carcinoma.